Clarification of methodology and further results from the pivotal phase 3 study of crisaborole for mild‐moderate atopic dermatitis

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles